Skip to content

Total investments at other companies

Sunrun logo
SunrunRUN
$17.03B+9.9%
Solaris Energy Infrastructure logo
Solaris Energy InfrastructureSEI
$1.96B+307%
Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
$68.09M
WillScot Holdings Corporation logo
WillScot Holdings CorporationWSC
$3.1B-7.8%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$27.29M+12.7%
Eastern Bankshares, Inc. logo
Eastern Bankshares, Inc.EBC
$38.8M+321%

Other financials

Income statement

See full
Revenue$149.4M+5.6%
Gross profit$134.9M+9.2%
Operating income$73.2M+15.6%
Net income$63.7M+12.3%
EPS (diluted)$0.50+11.1%

Balance sheet

See full
Cash & equivalents$755.9M+30.2%
Total debt$2.7M-13.3%
Total equity$1.0B+27.5%
Total assets$1.1B+26.3%

Cash flow

See full
Operating cash flow$59.6M-0.8%
CapEx$27.0K
Free cash flow$59.6M-0.8%

Valuation

See full
Market cap$3.84B+2.7%
Enterprise value$3.09B-4.1%
P/E17.4×-1.6×
P/S6.4×-0.6×

Profitability

See full
Gross margin86%-0.2pp
Operating margin44.8%+1.6pp
Net margin37.1%+0.2pp
FCF margin34.9%-15.2pp

Returns & leverage

See full
Return on equity24.5%-4.6pp
Debt / equity0.0×
Current ratio7.1×+1.0×

Where this comes from

Reported directly by Catalyst Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesFVNINoncurrent.

The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Catalyst Pharmaceutical's total investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Catalyst Pharmaceutical's total investments?
Catalyst Pharmaceutical (CPRX) reported total investments of $27.29M in Q1 2026.
How has Catalyst Pharmaceutical's total investments changed year-over-year?
Catalyst Pharmaceutical's total investments increased by 12.7% year-over-year, from $24.21M to $27.29M.
What does total investments mean?
This metric represents the aggregate carrying value of all long-term financial assets held by the company, including marketable securities, debt instruments, and other non-current investment vehicles. It reflects the firm's strategy for deploying excess liquidity into interest-bearing or capital-appreciating assets rather than holding cash equivalents. Monitoring this balance provides insight into the company's capital preservation strategy and its ability to generate non-operating income to support long-term research and commercialization efforts.